G44.89 — Primary Headache Disorder
Denied46F · investigation — MRI Brain
Insurer Rationale
The presentation is most consistent with migraine. Neuroimaging is deferred pending a trial of triptan therapy and diary-based outpatient reassessment.
Clinical Contradiction
Insurer states
“Neuroimaging is not routinely recommended for primary headache disorders”
Clinical evidence shows
New behavioural change and seizures are red-flag features — MRI is the only investigation that distinguishes benign headache from intracranial mass
Patient risk
Delayed brain tumour diagnosis can lead to irreversible neurological damage
Reasoning Chain
Headache, nausea, vomiting, and visual change are shared between primary headache disorders and brain tumours. New behavioural change and seizures are the discriminators, and MRI is the graph-linked investigation that separates benign headache from intracranial mass effect.
Reasoning Chain
Findings
Headache, Morning vomiting, Visual disturbance, Personality change, Recent focal seizure
Differential
Primary Headache Disorder (initial insurer assumption) vs Brain Tumour (not excluded)
Shared findings
Headache, Nausea, Vision change, Vomiting
Discriminating investigation — DENIED
MRI Brain
Identifies or excludes mass lesion, oedema, or hydrocephalus driving the red-flag headache pattern
Verdict
Denial is clinically unsafe. A medication trial does not address the mass-lesion differential when neurologic red flags have already emerged.
Clinical Evidence
NICE Guideline NG12 — Suspected cancer: recognition and referral
Brain and central nervous system cancers
Progressive headache with seizure or personality change warrants urgent imaging assessment.
British Association for the Study of Headache Guidelines (2024)
Red-flag features
Secondary headache features override routine primary headache management pathways and justify neuroimaging.